Verve Therapeutics Inc. (VERV)
NASDAQ: VERV
· Real-Time Price · USD
11.13
0.03 (0.27%)
At close: Jul 24, 2025, 3:59 PM
Verve Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -31.03M | -50.03M | -50.13M | -49.8M | -48.74M | -48.35M | -45.76M | -53.98M | -51.98M | -41.09M | -45.19M | -40.95M | -30.17M | -31.34M | -22.75M | -52.97M | -13.26M |
Depreciation & Amortization | 1.72M | 1.7M | 1.75M | 1.67M | 1.63M | 1.52M | 1.47M | 1.34M | 1.13M | 925K | 717K | 648K | 514K | 472K | 412K | 357K | 294K |
Stock-Based Compensation | 11.17M | 10.45M | 10.82M | 11.65M | 10.34M | 9.25M | 8.82M | 9.01M | 8.02M | 6.7M | 5.92M | 5.65M | 4.2M | 2.76M | 2.29M | 1.35M | 670K |
Other Working Capital | -12.04M | -2.71M | 1.04M | -488K | -904K | -3.94M | 28.28M | -2.97M | -1.49M | 2.06M | 10.3M | 3.74M | -2.5M | -3.52M | -4.43M | 2.41M | -4.2M |
Other Non-Cash Items | -251K | -111K | -924K | -3.42M | -2.28M | 9.69M | 923K | 2.35M | -2.96M | -2.69M | 4.47M | 63K | -448K | -642K | 645K | 36.01M | -778K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -10.56M | -3.49M | -3.7M | n/a | n/a | n/a | n/a | n/a | 740K | 412K | 148K | 208K |
Change in Working Capital | -9.45M | -2.85M | -1.12M | 5.75M | -4.04M | -2.22M | 26.22M | -2.98M | -3.31M | 3.25M | 4.91M | 7.83M | -7.61M | -34K | -2.37M | 1.76M | -2.27M |
Operating Cash Flow | -27.84M | -40.84M | -39.61M | -34.16M | -43.08M | -40.68M | -11.81M | -47.96M | -49.1M | -32.89M | -29.18M | -26.76M | -33.51M | -28.04M | -21.36M | -13.34M | -15.14M |
Capital Expenditures | -1.22M | -1.39M | -936K | -980K | -433K | -2.19M | -1.06M | -2.66M | -3.38M | -4.97M | -2.64M | -2.72M | -2.91M | -981K | -1M | -1.31M | -1.07M |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | 6.71M | 10.77M | -35.69M | -18.77M | 163.34M | 52.88M | -10.5M | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -144.82M | -73.07M | -74.83M | -111.91M | -164.19M | -122.32M | -147.94M | -113.12M | -133.75M | -257.32M | -147.83M | -74.25M | n/a | -137M | -223.31M | n/a | -11.18M |
Sales Maturities Of Investments | 97.87M | 104M | 132.58M | 143.04M | 122.99M | 115.61M | 137.17M | 148.81M | 152.52M | 93.98M | 94.95M | 84.75M | 63M | 81M | 12M | 19.8M | 23.96M |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | -6.71M | -10.77M | 35.69M | 18.77M | -163.34M | -52.88M | 10.5M | 63M | -56M | -211.31M | 19.8M | 12.78M |
Investing Cash Flow | -48.17M | 29.55M | 56.81M | 30.15M | -41.63M | -8.89M | -11.83M | 33.02M | 15.39M | -168.31M | -55.52M | 7.78M | 60.09M | -56.98M | -212.32M | 18.49M | 11.71M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 7K | 849K | 14K | 1.35M | 250K | 624K | 213K | 1.23M | 51K | 1.01M | 503K | 445K | 505K | 1.22M | -867K | 282.9M | 72K |
Financial Cash Flow | 7K | 25.15M | 14K | 1.3M | 22.73M | 177.38M | 31.92M | 1.23M | 2.04M | 39.6M | 288.41M | 445K | 505K | 1.22M | -867K | 282.9M | 93.83M |
Net Cash Flow | -76.01M | 13.85M | 17.22M | -2.71M | -61.98M | 127.81M | 8.28M | -13.7M | -31.67M | -161.61M | 203.72M | -18.53M | 27.09M | -83.8M | -234.54M | 288.05M | 90.4M |
Free Cash Flow | -29.07M | -42.23M | -40.54M | -35.14M | -43.52M | -42.87M | -12.87M | -50.62M | -52.47M | -37.86M | -31.81M | -29.48M | -36.41M | -29.02M | -22.36M | -14.65M | -16.21M |